•  
  •  
 

ORCID ID

Veinardi Madjid: -

David Calvin: 0009-0002-9400-7053

Gatot Purwoto: 0000-0001-5019-2707

Tofan Widya Utami: 0000-0002-0191-5902

Tricia Dewi Anggraeni: 0000-0002-8876-3138

Dhanasari Vidiawati: 0000-0001-7133-5009

Hariyono Winarto: 0000-0002-2081-9238

Abstract

Introduction: Nausea and vomiting (NV) remain as side effects of chemotherapy, which has a detrimental effect on patients’ quality of life (QOL) and treatment adherence. This study aimed to determine the effect of chemotherapy-induced NV (CINV) on the QOL of patients with ovarian cancer treated with chemotherapy at Dr. Cipto Mangunkusumo Hospital (CMH).

Methods: We conducted a cross-sectional study in patients with ovarian cancer receiving first-line chemotherapy regimens of carboplatin and paclitaxel. The European Organisation for Research and Treatment helped translate the Quality-of-Life Questionnaire-OV28 (QLQ-OV28) into Indonesian and tested it in a preliminary study. The approved Indonesian version of the QLQ-OV28, with the Quality-of-Life Questionnaire-C30 (QLQ-C30), was then used to evaluate QOL before and 1 week after chemotherapy.

Results: Several symptom scales increased, whereas function scales decreased. Moreover, 72.5% had an increase in the NV symptom scale, whereas 67.5% had a decrease in patients’ scale after chemotherapy. CINV had a significant partial effect on reducing QOL (p = 0.047 and y = 12.208–0.432).

Conclusions: CINV has a significant influence on lowering the QOL of patients with ovarian cancer undergoing first-line chemotherapy regimens with carboplatin and paclitaxel in CMH.

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
  2. Lee JY, Kim S, Kim YT, Lim MC, Lee B, Jung KW, et al. Changes in ovarian cancer survival during the 20 years before the era of targeted therapy. BMC Cancer. 2018;18:601.
  3. Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019;30:672–705.
  4. Berek JS, MD NFH. Berek and Hacker’s gynecologic oncology. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2020. p. 975.
  5. Amjad MT, Chidharla A, Kasi A. Cancer chemotherapy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.
  6. Dunton CJ. Management of treatment-related toxicity in advanced ovarian cancer. Oncologist. 2002;7 Suppl 5:11–9.
  7. Rapoport BL, Molasiotis A, Raftopoulos H, Roila F. Chemotherapy-Induced Nausea and Vomiting. Biomed Res Int. 2015;2015:457326.
  8. Akbarali HI, Muchhala KH, Jessup DK, Cheatham S. Chemotherapy induced gastrointestinal toxicities. Adv Cancer Res. 2022;155:131–66.
  9. Abola MV, Prasad V, Jena AB. Association between treatment toxicity and outcomes in oncology clinical trials. Ann Oncol. 2014;25:2284–9.
  10. Börjeson S, Hursti TJ, Tishelman C, Peterson C, Steineck G. Treatment of nausea and emesis during cancer chemotherapy. Discrepancies between antiemetic effect and well-being. J Pain Symptom Manage. 2002;24:345–58.
  11. Bezjak A, Tu D, Bacon M, Osoba D, Zee B, Stuart G, et al. Quality of life in ovarian cancer patients: Comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study. J Clin Oncol. 2004;22:4595–603.
  12. Haiderali A, Menditto L, Good M, Teitelbaum A, Wegner J. Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population. Support Care Cancer. 2011;19:843–51.
  13. Giesinger JM, Kuijpers W, Young T, Tomaszewski KA, Friend E, Zabernigg A, et al. Thresholds for clinical importance for four key domains of the EORTC QLQ-C30: Physical functioning, emotional functioning, fatigue and pain. Health Qual Life Outcomes. 2016;14:87.
  14. Gallardo-Rincón D, Toledo-Leyva A, Bahena-González A, Montes-Servín E, Muñoz-Montaño W, Coronel-Martínez J, et al. Validation of the Mexican-Spanish version of the EORTC QLQ-OV28 instrument for the Assessment of Quality of Life in Women with ovarian cancer. Arch Med Res. 2020;51:690–9.
  15. Perwitasari DA, Atthobari J, Dwiprahasto I, Hakimi M, Gelderblom H, Putter H, et al. Translation and Validation of EORTC QLQ-C30 into Indonesian Version for Cancer Patients in Indonesia. Jpn J Clin Oncol. 2011;41:519–29.
  16. Kuli D, Velikova G, Greimel E, Koller M. EORTC quality of life group translation procedure. 4th ed. Brussels, Belgium: EORTC; 2017.
  17. ECOG-ACRIN Cancer Research Group. ECOG Performance Status Scale. Philadelphia, PA: ECOG-ACRIN Cancer Research Group, 2024.
  18. Navari RM. 5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy. Biochim Biophys Acta. 2015;1848:2738–46.
  19. Tan HS, Dewinter G, Habib AS. The next generation of antiemetics for the management of postoperative nausea and vomiting. Best Pract Res Clin Anaesthesiol. 2020;34:759–69.
  20. Rao KV, Faso A. Chemotherapy-induced nausea and vomiting: Optimizing prevention and management. Am Health Drug Benefits. 2012;5:232–40.
  21. Fayers P, Aaronson N, Bjordal K, Groenvols M, Bottomley A. EORTC QLQ-C30 scoring manual. 3rd ed. Brussels, Belgium: EORTC; 2001.
  22. Greimel E, Bottomley A, Cull A, Waldenstrom AC, Arraras J, Chauvenet L, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer. 2003;39:1402–8.
  23. Paradowski J, Tomaszewski KA, Bereza K, Tomaszewska IM, Pasternak A, Paradowska D, et al. Validation of the Polish version of the EORTC QLQ-OV28 module for the assessment of health-related quality of life in women with ovarian cancer. Expert Rev Pharmacoecon Outcomes Res. 2014;14:157–63.
  24. Perrone F, Jommi C, Maio MD, Gimigliano A, Gridelli C, Pignata S, et al. The association of financial difficulties with clinical outcomes in cancer patients: Secondary analysis of 16 academic prospective clinical trials conducted in Italy. Ann Oncol. 2016;27:2224–9.
  25. Kim SI, Lee Y, Lim MC, Joo J, Park K, Lee DO, et al. Quality of life and sexuality comparison between sexually active ovarian cancer survivors and healthy women. J Gynecol Oncol. 2015;26:148–54.
  26. Chie W, Lan C, Chiang C, Chen C. Quality of life of patients with ovarian cancer in Taiwan: Validation and application of the Taiwan Chinese version of the EORTC QLQ‐OV28. Psychooncology. 2010;19(7):782–5.

Creative Commons License

Creative Commons Attribution-Share Alike 3.0 License
This work is licensed under a Creative Commons Attribution-Share Alike 3.0 License.

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.